Misonix to Exhibit at NASS 2017
October 12 2017 - 12:00PM
Misonix, Inc. (NASDAQ:MSON), a provider of
minimally invasive therapeutic ultrasonic medical devices that
enhance clinical outcomes, today announced that it will participate
in the 2017 North American Spine Society (“NASS”) 32nd Annual
Meeting to be held at the Orange County Convention Center in
Orlando, Florida from October 25 -28, 2017.
Stavros Vizirgianakis, chief executive officer of Misonix, will
deliver an analyst presentation on Wednesday, October 25 at 3:30 pm
ET at the Misonix booth - #765 – to review the company’s
technology, products, and corporate developments.
About NASSThe North American Spine Society
(“NASS”) is a global multidisciplinary medical society that
utilizes education, research and advocacy to foster the highest
quality, ethical, value- and evidence-based spine care for
patients.
About MisonixMisonix, Inc. designs, develops,
manufactures and markets therapeutic ultrasonic medical devices.
Misonix's therapeutic ultrasonic platform is the basis for several
innovative medical technologies. Addressing a combined market
estimated to be in excess of $1.5 billion annually; Misonix's
proprietary ultrasonic medical devices are used in spine surgery,
neurosurgery, orthopedic surgery, wound debridement, cosmetic
surgery, laparoscopic surgery, and other surgical and medical
applications. Additional information is available on the
Company's Web site at www.misonix.com.
Safe Harbor StatementWith the exception
of historical information contained in this press release, content
herein may contain "forward looking statements" that are made
pursuant to the Safe Harbor Provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based on
management's current expectations and are subject to uncertainty
and changes in circumstances. Investors are cautioned that
forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements
made. These factors include general economic conditions, delays and
risks associated with the performance of contracts, risks
associated with international sales and currency fluctuations,
uncertainties as a result of research and development, acceptable
results from clinical studies, including publication of results
and patient/procedure data with varying
levels of statistical relevancy, risks involved in introducing and
marketing new products, potential acquisitions, consumer and
industry acceptance, litigation and/or court proceedings, including
the timing and monetary requirements of such activities, the timing
of finding strategic partners and implementing such relationships,
regulatory risks including approval of pending and/or contemplated
510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, the impact of the
pending investigation by the Department of Justice and Securities
Exchange Commission, and other factors discussed
in the Company's Annual Report on Form 10-K, subsequent Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K. The Company
disclaims any obligation to update its forward-looking
relationships.
Corporate Contact Misonix
Contact:
Joseph
Dwyer
631-694-9555invest@misonix.com
Investor ContactJoe
Diaz
Lytham
Partners
602-889-9700 info@misonix.com
Misonix (NASDAQ:MSON)
Historical Stock Chart
From Mar 2024 to Apr 2024
Misonix (NASDAQ:MSON)
Historical Stock Chart
From Apr 2023 to Apr 2024